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Mechanism of Progression of Renal Insuffi ciency in Rat with Glomerulosclerosis
Hiroe Imai (Department of Nephrology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 350-0495, Japan)
Objective: To investigate the role of the renin-angiotensin system and sodium in the pathogenesis of 
glomerulosclerosis, I examined the effect of angiotensin converting enzyme inhibitor (ACEI) and angiotensin II 
receptor blocker (ARB) on blood pressure and renal function in rat with glomerulosclerosis, Milan normotensive 
rats (MNS). Method: Experiment 1: Twenty-four 8-week old MNS were divided into three groups as follows (1) 
Normal-salt diet group (0.5％NaCl), (2) Low-salt diet group (0.1％NaCl), and (3) High-salt diet group (6.0％NaCl). 
Each diet was given for 32 weeks. Experiment 2: Twenty-four 8-week old MNS were divided into three groups as 
follows (1) ACEI treated group (Delapril 10mg/kg/day), (2) ARB treated group (CV-116 3mg/kg/day), and (3) 
placebo treated group (control). Each of these antihypertensive drug was administrated per os for 32 weeks. In 
both studies, during the experiment, body weight, blood pressure and urinary excretion of protein were measured 
every four weeks. At the end of study, after measurement of plasma angiotensin I, angiotensin II, aldosterone 
and renin activity, renal tissues were obtained for light microscopic examination and for measurements of AT1a 
receptor, AT2 receptor, ecNOS and HO-1 mRNA by using RT-PCR. Results: Experiment 1: During the experiment, 
renin-angiotensin system was high level in normal salt-diet group and it was more activated in low salt-diet. There 
were no signifi cant differences in blood pressure in three groups. Marked glomerulosclerosis and interstitial cell 
infi ltration, which were found in MNS were signifi cantly aggravated by low-salt diet. On the contrary, glomerular 
changes were signifi cantly ameliorated by high-salt diet. Experiment 2: Systolic blood pressure and urinary excretion 
of protein in MNS was signifi cantly reduced by administration of ACEI. ACEI treatment induced signifi cant elevation 
of the expression of AT2 receptor, ecNOS and HO-1 mRNA in the kidney. ARB treatment induced signifi cant 
reduction of the expression of ecNOS and HO-1 mRNA in the kidney. Marked glomerulosclerosis and interstitial 
cell infi ltration, which were found in the control group were signifi cantly ameliorated by treatment of ACEI. On the 
contrary, there was no signifi cant improvement in ARB treated group. Conclusion: From these data, I concluded 
that histopathological change in the kidney in MNS was determined by the activation of renin-angiotensin system. On 
the contrary, nitric oxide and heme-oxygenase plays as the protective role in the renal insuffi ciency. Furthermore, 
ACEI and ARB were different from renalprotective effect in rat with glomerulosclerosis.
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存後RNAを抽出し，endothelial nitric oxide synthetase 
（ecNOS），heme-oxygnase-1（HO-1），angiotensin 
II type 1a （AT1a）受容体，angiotensin II type 2（AT2）
受容体のm R N Aの発現を，半定量的 R e v e r s e  
Transcription-Polymerase Chain Reaction（RT-PCR）法
を用いて確認した．
実験2. Milan normotensive ratの腎障害進展におよぼ
すRenin-Angiotensin（R-A）系に関する実験
8週齢のM N S雄（n＝24）を，placebo群：0.5％
NaCl食＋1 ％ エ タ ノ ー ル 溶 液　1 ml/day（n＝8），
ACEI群：0.5％ NaCl食＋Angiotensin conver ting 
enzyme阻害薬（ACEI）：Delapril 10 mg/kg/day








































い，そしてトレーサー溶液として 125 I- angiotensin I，




















ーゼ反応polymerase chain reaction（PCR）をGeneAmp 
PCR sysem 9600  （Perkin-Elmer, Inc, MA, USA）を用い
て行った．
DEPC処理水に溶かしたRNAのDnase I処理を
行 っ た．DNase I 10×Buffer，DNase I amplification 




primer（GIBCO BRL. Rockville, MD,USA） 3μ l，5×
first Buffer 6 μ l，dithiothreitol（DTT） 3μ l，dNTP 
mixture（TAKARA，  東京） 6μ l，逆転写酵素である
Super script II （GIBCO BRL.Rockville,MD,USA） 0.7
μ lを加え，42℃，60分で保温し，RT反応をさせた．
こ のcDNA 1μ lにDEPC処 理 水 32.5μ l， Dimethyl 
Sulfoxide （DMSO, SIGMA-ALDRICH, MU, USA）5μ l，
10×PCR Buffer （TAKARA，東京） 5μ l，dNTP mixture 
4μ l，Forward Primer  （Fw）1μ l，Reverse Primer（Rv）
1μ l，rTaq polymerase （TAKARA，東京） 0.5μ l を加え

















塩基配列のGene Bank accession numberおよび，PCR 
fragment sizeを示す．
ecNOS primer （AF85195, 587bp）
Fw:5’-GCAGCATCACCTACGATACC-3’
Rv:5’-CTCAGTGATCTCCACGTTGG-3’
AT1a primer （M86912, 375bp）
Fw:5’-CATGAAGCTGAAGACTGTGGC-3’
Rv:5’-GCGCACACTGTGATATTGG-3’
AT2 primer （U22663, 1126bp）
Fw:5’-TTGCTGCCACCAGCAGAAAC-3’
Rv:5’-GTGTGGGCCTCCAAACCATTGCTA-3’
HO-1 primer （J02722, 450bp）
Fw:5’-TGGAAGAGGAGATAGAGCGA-3’,
Rv:5’-TGTTGAGCAGGAAGGCGGTC-3’









光学顕微鏡Olympus provis AX80T-64FLBD（Olympus 




















c. 間質病変の比較（Interstitial cell infiltration score）
間質病変についてはNakamotoらの報告29)に基づき，
Interstitial cell infiltration scoreを計算した．強拡大一
視野中の間質の細胞浸潤数を計測し，その20視野の




はMacintoshのStatview IV（SAS Institute Inc NC USA）
を使用した．血圧，体重，尿量，尿蛋白排泄量，尿中
Na排泄量，尿中K排泄量ならびに尿中Na/Kについて
は，Two-way analysis of varianceを用いて群間比較を
行った後，Scheffe’s Fを行い，また血漿ホルモンの変
化，Sclerosis Index，Interstitial cell infiltration score，
Arteriolosclerosis Index，血清Na，K，Cl，BUN，Crtnn
濃度ならびにRT-PCRのデータについては，One-way 
analysis of varianceを用いた後，Scheffe’s Fを行い，
統計上p＜0.05をもって有意差ありとした．
結　果











Fig. 1. Effects of low- or high-salt diet on systolic blood pressure (SBP) and body weight in MNS. Values are expressed as 
























Fig. 3. Changes in urinary excretion of sodium (Na), potassium (K) and Na/K ratio with low- or high-salt diet treated MNS. Values 
are expressed as means±SEM. **P＜0.01, *P＜0.05, statistically signifi cant difference compared with normal-salt diet group.
Fig. 2. Effects of low- or high-salt diet on urinary excretion of protein and urinary volume in MNS. Values are expressed as 


















正塩食群で糸球体の硬化（Sclerosis Index : 2.0±
0.16）ならびに間質の線維化，尿細管障害および間質へ
の細胞浸潤を認めた（Interstitial cell infiltration score : 
558±47）．それは，減塩食群で増悪（Sclerosis Index 
: 2.3±0.18, P＜0.05，Interstitial cell infiltration score 
: 607±51, P＜0.05）を，加塩食群で改善（Sclerosis 
Index : 1.6±0.12, P＜0.05. Interstitial cell infiltration 
score : 310±26, P＜0.05.）を認めた（Fig. 5, 6）．
（6）腎臓におけるAT1a受容体 , AT2受容体 , ecNOS, 
HO-1mRNAの発現
Fig. 4. Effects of low- or high-salt diet on plasma renin-angiotensin system level in MNS. Values are expressed as means±
SEM. **P＜0.01, *P＜0.05, statistically signifi cant difference compared with normal-salt diet group. 
Fig. 5. Pathological changes of glomerulosclerosis and interstitial nephropathy in low- or high-salt diet treated MNS. 
Marked glomerulosclerosis and interstitial cell infiltration were found in low-salt diet treated group. Glomerular changes 



















± 9.5 gが 40週齢で 268.5± 20.2 g，ARB群は 8週齢
で 186.5± 9.3 gが 40週齢で 291.7± 22.8 gと有意な
差は認められなかった．血圧の経時的変化は，40週




Fig. 6. Changes in sclerosis index, interstitial cell infiltration score and arteriolosclerosis index with low- or high-salt 
diet in MNS. Values are expressed as means±SEM. **P＜0.01, *P＜0.05, statistically significant dif ference compared 
with normal-salt diet group.
Fig. 7. Expressions of AT1a mRNA, AT2 mRNA, eNOS mRNA and HO-1 mRNA analyzed by semi-quantitative RT-PCR. 
RNA was isolated from kidny in MNS. Lane 1 showed low-salt diet group, lane 2 showed normal-salt diet group and 
lane 3 showed high-salt diet group. Values are expressed as means±SEM. **P＜0.01, *P＜0.05, statistically significant 




で，placebo群 は11.5±1.0 ml/day，ACEI群 は9.8±
0.8ml/day，ARB群は12.8±1.2 ml/dayであった．


















Fig. 8. Effects of oral administration of ACEI or ARB on systolic blood pressure (SBP) and body weight in MNS.  Values are 
expressed as mean±SEM. **P＜0.01, *P＜0.05, statistically signifi cant difference compared with placebo group at identical times.
Fig. 9. Effects of oral administration of ACEI or ARB on urinary excretion of protein and urine volum in MNS.  Values are 





（placebo群 : Sclerosis Index : 2.1±0.16，Interstitial cell 
infiltration score : 516±48，ARB群 : Sclerosis Index: 
2.2±0.18，Interstitial cell infiltration score : 538±
42），一方，ACEI群では有意な改善を認めた（ACEI: 
Sclerosis Index : 1.8±0.08，Interstitial cell infiltration 





















Fig. 10. Effects of oral administration of ACEI and ARB on plasma renin-angiotensin system in MNS.  Values are expressed as 
means±SEM.  **P＜0.01, *P＜0.05, statistically signifi cant difference compared with placebo group. 
(a)
   Na(mEq/L)     K(mEq/L)    Cl(mEq/L)  BUN(mg/dl)  Crtnn(mg/dl)
0.5%NaCl-MNS   142.7 ± 2.0    4.0 ± 0.3  109.6 ± 0.08  22.9 ± 3.0   0.4 ± 0.08
0.1%NaCl-MNS   140.4 ± 2.0    3.9 ± 0.3  110.2 ± 0.12  29.5 ± 2.8   1.2 ± 0.11+
6.0%NaCl-MNS   142.4 ± 2.8    4.5 ± 0.2  108.5 ± 0.07  21.6 ± 3.6   0.2 ± 0.06
(b)
  Na(mEq/L)      K(mEq/L)   Cl(mEq/L)  BUN(mg/dl)  Crtnn(mg/dl)
0.5%MNS(placebo)   141.8 ± 2.0    4.2 ± 0.4  107.8 ± 0.05   20.5 ± 3.1   0.5 ± 0.08
0.5%MNS+ACEI   142.2 ± 2.1    4.6 ± 0.2  106.6 ± 0.06   17.7 ± 2.9   0.3 ± 0.08
0.5%MNS+ARB   143.2 ± 2.0    4.8 ± 0.5  111.6 ± 0.08   24.4 ± 2.2   0.8 ± 0.12
+ P＜ 0.05 vs. 0.5%NaCl-MNS
Table 1. (a) Changes in serum sodium (Na), potassium (K), chloride (Cl), blood urea nitrogen (BUN) and creatinine 
(Crtnn) in low- and high-salt diet treated MNS. Values are expressed as means±SEM. ＋P＜0.05, statistically signifi cant 
differense compared with normal-salt diet group. (b) Changes in serum sodium (Na), potassium (K), chloride (Cl), blood 






























Fig. 12. Changes in sclerosis index, interstitial cell infi ltration score and arteriolosclerosis index with oral administration of 
ACEI or ARB in MNS. Values are expressed as means±SEM. **P＜0.01, *P＜0.05, statistically signifi cant difference compared 
with placebo group.
Fig. 11. Pathological changes of glomerulosclerosis and interstitial nephropathy in ACEI or ARB treated MNS.  Marked 
glomerulosclerosis and interstitial cell infi ltration, which were found in the placebo group was signifi cantly ameliorated by 


























































Fig. 13. Expressions of AT1a mRNA, AT2 mRNA, ecNOS mRNA and HO-1 mRNA analyzed by semi-quantitative RT-PCR. 
RNA was isolated from kidny in MNS. Lane 1 showed placebo group, lane 2 showed ACEI group and lane 3 showed ARB group. 
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